Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is gearing up for the sixth annual BOTOX® Cosmetic Day, set for Wednesday, November 20, 2024. This special day celebrates the healthcare providers and patients who have helped make BOTOX® Cosmetic the world’s…
Second Round of Polio Vaccination Campaign in Gaza Completed Amid Ongoing Conflict: UNICEF and WHO The second round of the polio vaccination campaign in the Gaza Strip concluded yesterday, with 556,774 children under the age of 10 receiving a second…
The Access and Allocation Mechanism (AAM) for mpox has allocated an initial 899,000 vaccine doses to nine African countries severely impacted by the ongoing mpox outbreak. This distribution, made in collaboration with affected nations and donors, aims to ensure effective…
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, will showcase new findings from the Phase 3 CARTITUDE-4 trial on minimal residual disease (MRD) negativity rates in multiple myeloma patients treated with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus standard…
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-driven cancers, reported its third-quarter financial results for the period ending September 30, 2024, and shared updates on corporate progress. The company’s mission centers on…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) showcased findings from the long-term KINECT®-4 study, revealing that nearly 60% of participants achieved remission from tardive dyskinesia after 48 weeks of treatment with once-daily INGREZZA® (valbenazine) capsules. This research, titled “Remission of Tardive Dyskinesia…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) recently presented data from over 300 patients with tardive dyskinesia treated with INGREZZA® (valbenazine) capsules, revealing significant improvements in functional, social, emotional, and health-related quality of life. These findings, drawn from Phase 3 and 4…
A recent World Health Organization (WHO) study, published in eBioMedicine, has identified 17 priority pathogens that are endemic in various communities and urgently require new vaccines. This marks WHO’s first global effort to systematically prioritize endemic pathogens for vaccine development,…
Libra Therapeutics, Inc., a private biotechnology company focused on developing innovative therapies to restore cellular balance and reduce neurodegeneration, has announced the appointment of Shawn A. Scranton, PharmD, as President and Chief Executive Officer. Dr. Scranton brings 30 years of…
On the morning of October 30, Ma Xin, a member of the Standing Committee of the Jiangsu Provincial Party Committee and Executive Vice Governor, visited Jiangsu Hansoh, a subsidiary of Hansoh Pharma. Accompanying him were Yang Xinchong, Secretary-General of the…
The 2024 American Society of Nephrology (ASN) Kidney Week conference took place at the San Diego Convention Center from October 23 to 27. During this event, a post-hoc analysis of Hansoh Pharma’s innovative drug, pegmolesatide (trade name: Saint Luolai), for…
On World Cities Day, the World Health Organization (WHO) launched a new report highlighting how urban areas can tackle the increasing challenges posed by noncommunicable diseases (NCDs) and injuries. As urbanization is expected to rise to 68% by 2050, the…
